Evidence map›Paper›PMID 39034407›Full record

ReviewJournal of nanobiotechnology2024

Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges.

Shujing Ren, Yuhang Xu, Xingpeng Dong, Qingxin Mu, Xia Chen, Yanyan Yu, Gaoxing Su

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Rheumatoid Arthritis Therapy Based on B Cells.Drug design, development and therapy · 2025
    Review
  20. Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shujing RenDepartment of Pharmacy, Affiliated Hospital 2 of Nantong University, Nantong, 226000, PR China.
Yuhang XuSchool of Pharmacy, Nantong University, Nantong, 226000, PR China.
Xingpeng DongSchool of Pharmacy, Nantong University, Nantong, 226000, PR China.
Qingxin MuDepartment of Pharmaceutics, University of Washington, Seattle, WA, 98195, USA.
Xia ChenDepartment of Pharmacy, Affiliated Hospital 2 of Nantong University, Nantong, 226000, PR China. cxia66@126.com.
Yanyan YuSchool of Pharmacy, Nantong University, Nantong, 226000, PR China. yuyanyan@ntu.edu.cn.
Gaoxing SuSchool of Pharmacy, Nantong University, Nantong, 226000, PR China. sugaoxing@ntu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease with multifactorial etiology and intricate pathogenesis. In RA, repeated monotherapy is frequently associated with inadequate efficacy, drug resistance, and severe side effects. Therefore, a shift has occurred in clinical practice toward combination therapy. However, conventional combination therapy encounters several hindrances, including low selectivity to arthritic joints, short half-lives, and varying pharmacokinetics among coupled drugs. Emerging nanotechnology offers an incomparable opportunity for developing advanced combination therapy against RA. First, it allows for co-delivering multiple drugs with augmented physicochemical properties, targeted delivery capabilities, and controlled release profiles. Second, it enables therapeutic nanomaterials development, thereby expanding combination regimens to include multifunctional nanomedicines. Lastly, it facilitates the construction of all-in-one nanoplatforms assembled with multiple modalities, such as phototherapy, sonodynamic therapy, and imaging. Thus, nanotechnology offers a promising solution to the current bottleneck in both RA treatment and diagnosis. This review summarizes the rationale, advantages, and recent advances in nano-empowered combination therapy for RA. It also discusses safety considerations, drug-drug interactions, and the potential for clinical translation. Additionally, it provides design tips and an outlook on future developments in nano-empowered combination therapy. The objective of this review is to achieve a comprehensive understanding of the mechanisms underlying combination therapy for RA and unlock the maximum potential of nanotechnology, thereby facilitating the smooth transition of research findings from the laboratory to clinical practice.

Indexed as

Arthritis, RheumatoidAnimalsAntirheumatic AgentsCombined Modality TherapyDrug Delivery SystemsHumansNanomedicineNanoparticlesNanostructuresNanotechnologyAntirheumatic AgentsCo-deliveryCombination therapyMultifunctional nanomedicineMultimodal therapyRheumatoid arthritis

Identifiers

PMID39034407
PMCPMC11265020

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.